Abstract
A common cause of Parkinson disease are missense mutations in the leucine-rich repeat kinase 2 (LRRK2) catalytic Roc-COR domain, leading to a decrease in GTPase activity; and its kinase domain, leading to an increase in kinase activity and subsequent LRRK2 toxicity. Targeting LRRK2 with selective, brain-permeable kinase inhibitors is a promising approach to reduce toxicity, and thus is a major goal of clinical development. Understanding the specific signaling cascades triggered by LRRK2 mutations will be key to this aim. This article is part of a special issue on Parkinson disease.
Original language | English (US) |
---|---|
Pages (from-to) | 75-76 |
Number of pages | 2 |
Journal | Journal of neurochemistry |
DOIs |
|
State | Published - Oct 1 2016 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Cellular and Molecular Neuroscience